SHINE Medical Technologies and Phoenix have completed a merger under which Phoenix has become a wholly owned subsidiary of SHINE, the companies announced today. “SHINE and Phoenix have shared a…

Promega has opened the Kornberg Center, its newly constructed research and development facility, the company announced today. According to a release, the three-story, 280,000-square-foot building will support core product and technology…

Stem Pharm has been awarded a $1.7 million SBIR grant from the National Institute of Environmental Health Sciences of the National Institutes of Health (NIH), the company announced recently. According…

SHINE Medical Technologies has completed exterior construction of its medical isotope production facility and made it weathertight for protection, the company announced today. According to a release, the facility can withstand…

BioForward and BIOQuebec, Quebec’s largest biosciences network, will sign a memorandum of understanding to form a cooperative relationship, the organizations announced recently. “This step will take us both a long…

HealthMyne’s radiomic and quantitative imaging solution was used in a lung carcinoma study that was published in Cancer Control, the company announced recently. According to a release, the study demonstrated HealthMyne’s…

Cellectar Biosciences has received another patent by the Japanese Patent Office, this time for its proprietary phospholipid-ether (PLE), the company announced today. According to a release, the patent provides composition…

NorthStar Medical Radioisotopes and Ion Beam Applications (IBA), a provider of proton therapy solutions for the treatment of cancer, expanded its collaboration to increase the global availability of technetium-99m (Tc-99m),…

NorthStar Medical Radioisotopes is making organizational changes to drive focused growth for its therapeutic and specialized single photon emission computed tomography (SPECT) radioisotopes business, the company announced today. “NorthStar is…

Exact Sciences has acquired Ashion Analytics to help accelerate the development of its precision oncology portfolio, including minimal residual disease (MRD) and other sequencing-based tests, the company announced recently. According…